期刊
BIOORGANIC & MEDICINAL CHEMISTRY
卷 26, 期 11, 页码 2928-2936出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2018.02.043
关键词
Metallo-beta-lactamase; Antibiotic resistance; Carbapenemase; Inhibitors; Structure activity relationships
资金
- Wellcome Trust
- Medical Research Council
- EU H2020 Marie Sklodowska-Curie [657314]
- Diamond Light Source [mx9306, mx12346, lb16949]
- EPSRC CDT SBM [EP/L015838/1]
- Clarendon Scholarship
- MRC [MR/L007665/1] Funding Source: UKRI
Metallo-beta-lactamases (MBLs) enable bacterial resistance to almost all classes of beta-lactam antibiotics. We report studies on enethiol containing MBL inhibitors, which were prepared by rhodanine hydrolysis. The enethiols inhibit MBLs from different subclasses. Crystallographic analyses reveal that the enethiol sulphur displaces the di-Zn(II) ion bridging 'hydrolytic' water. In some, but not all, cases biophysical analyses provide evidence that rhodanine/enethiol inhibition involves formation of a ternary MBL enethiol rhodanine complex. The results demonstrate how low molecular weight active site Zn(II) chelating compounds can inhibit a range of clinically relevant MBLs and provide additional evidence for the potential of rhodanines to be hydrolysed to potent inhibitors of MBL protein fold and, maybe, other metallo-enzymes, perhaps contributing to the complex biological effects of rhodanines. The results imply that any medicinal chemistry studies employing rhodanines (and related scaffolds) as inhibitors should as a matter of course include testing of their hydrolysis products. (C) 2018 The Authors. Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据